Dana-Farber Cancer Institute | Strategic Alliance Partners

January 23, 2025

Bradley McGregor, MD, discusses next steps for research with ipilimumab plus nivolumab for patients with diverse bladder cancer histologies.

January 22, 2025

Stem cell transplant programs at the Dana-Farber Brigham Cancer Center received outstanding reviews from the CIBMTR.

January 20, 2025

Bradley McGregor, MD, discusses the rationale for investigating nivolumab plus ipilimumab in advanced, rare genitourinary malignancies.

January 17, 2025

Treatment with avapritinib was associated with dynamic changes in bone density based on lumbar T-scores among patients with systemic mastocytosis.

January 16, 2025

Dana-Farber Cancer Institute and Gustave Roussy have announced that the topic of the Fourth Transatlantic Exchange in Oncology Conference will be “Radiopharmaceutical Therapy Meets Oncology.”

January 15, 2025

Bradley McGregor, MD, discusses the findings from a phase 2 study of nivolumab plus ipilimumab in rare GU cancers.

January 13, 2025

Erica L. Mayer, MD, MPH, responses with preoperative niraparib plus dostarlimab in patients with BRCA-mutant, ER-positive, HER2-negative breast cancer.

January 09, 2025

Daniel DeAngelo, MD, PhD, discusses the expanded role of blinatumomab in B-cell precursor acute lymphoblastic leukemia management

January 08, 2025

Dana-Farber Cancer Institute will launch the Center for RAS Therapeutics to advance scientific investigation and clinical care for RAS-driven cancers.

January 08, 2025

Fixed-duration zanubrutinib/venetoclax elicited responses in patients with relapsed/refractory chronic lymphocytic leukemia.

January 08, 2025

Toni Choueiri, MD, details the PFS outcomes and safety profiles for tivozanib plus nivolumab vs tivozanib alone in metastatic renal cell carcinoma

January 07, 2025

Daniel DeAngelo, MD, PhD, discusses the FDA approval of blinatumomab in the consolidation phase in CD19-positive, Ph-negative B-cell precursor ALL.

January 07, 2025

Daniel DeAngelo, MD, PhD, discusses the effect of avapritinib on bone density in patients with advanced systemic mastocytosis.

January 06, 2025

A study published in Science by researchers from Dana-Farber Cancer Institute demonstrated that rare germline genetic abnormalities could increase the risk of childhood cancers.

December 31, 2024

After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and testing checkpoint inhibitors across this malignancy, among several other achievements.

December 27, 2024

Understanding Waldenström Macroglobulinemia, and genomic profiles influencing clinical presentation and treatment strategies.

December 20, 2024

Elizabeth Buchbinder, MD, discusses the implications of the FDA's decision to grant breakthrough therapy designation to RP1 plus nivolumab in melanoma.

December 18, 2024

Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.

December 14, 2024

Erica L. Mayer, MD, MPH, discusses findings with neoadjuvant niraparib plus dostarlimab in ER-positive, HER2-negative, BRCA/PALB2-mutated breast cancer.

December 12, 2024

Dana-Farber Cancer Institute investigators found that women reported having similar QOL whether they received active monitoring or surgery for low-risk ductal carcinoma in-situ.